Oxford Nanopore Technolo... Share Discussion Threads

[brucie5] 04/9/2024 13:55

1.40 was the chart signal I was waiting for, but managed somewhat below. A momentum buy. In retrospect the prices on offer below £1 were a gift. It's managed now to slip above the 200sma, So now it does have to hold to retain this chart BO.

[brucie5] 04/9/2024 13:17

Bought back in. Time to sell.
;)

[eeza] 04/9/2024 12:02

That's jinxed it !

[palisz] 04/9/2024 11:51

ONT up 10p ( 7% ) @ 137.5p probably helping !!

[brucie5] 04/9/2024 08:51

Thanks. I believe there were some sizeable buys yesterday and the share is strong this morning in a battered market.

[bamboo2] 04/9/2024 07:48

Tencent's holding history. Dilution.

2., Image Frame Investment (HK) Limited(2) 63,117,700 8.89% 63,117,700 7.94% 63117700 6.708254 %

[brucie5] 03/9/2024 20:59

That makes sense, thanks.

[bamboo2] 03/9/2024 20:17

Tencent been in from the start, probably diluted. Will check later.

[p1nkfish] 03/9/2024 20:02

Was 7.35% end of 2023 in annual report.

[brucie5] 03/9/2024 19:05

Is TenCent new on the register at 6%? No sign of previous on the RNS.

[seball] 03/9/2024 13:48

Berenberg Bank Buy Recommendation today 3.9.24

282p

[brucie5] 03/9/2024 08:49

Reassuring results, but the chart seems stuck at current level, with some risk to buyers who rush in to buy shares on the spike, only to see it subside. The worst seems over, as we wait for the new chapter to begin.

[seball] 03/9/2024 06:59

Strong results and increasing margins. Buy and Hold

• Oxford Nanopore Technologies reported its interim results for the six months ended June 30, 2024.

• Revenue was flat at constant currenc, in line with expectations.

• Underlying revenue, excluding COVID sequencing and the Emirati Genome Program, increased by 12.4% at constant currency.

• Gross margin improved by 120 basis points to 58.8%, driven by underlying margin improvements and offsetting product mix and currency headwinds.

• The company reiterated its full-year guidance, expecting underlying revenue growth of 20-30% at constant currency and a gross margin of approximately 57%.

Most relevant - ). The Group is in discussion with the FCA and will formally apply for admission to the ESCC segment by the end of 2024, subject to meeting the required eligibility criteria. The step up to the ESCC segment would make Oxford Nanopore eligible for FTSE indexation.

[bamboo2] 03/9/2024 06:49

03 September 2024

Oxford Nanopore Technologies plc

Interim results for the six months ended 30 June 2024

Solid underlying growth despite end-market headwinds; new customer wins and continued commercial momentum support reaffirmation of full year guidance

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company behind a new generation of molecular sensing technology based on nanopores, today announces its interim results for the six months ended 30 June 2024.

Gordon Sanghera, Chief Executive Officer, commented:

"Against a challenging backdrop, our financial and operational performance in the first half was solid and in-line with our expectations, underpinning confidence in full year guidance. We delivered robust underlying revenue growth of 12.4% constant currency and margin expansion of 120bps.

"We continued with our high pace of innovation in the first half, with new product launches and platform enhancements. For example, we delivered the two product launches aimed at our regulated customer base, GridION Q-Line and Early Access of ElysION, our fully automated samples to answer product. These meet customer needs for routine, end-to-end analyses, for example in clinical and applied industrial markets, particularly with Biopharma customers.

"As we look forward, our highly differentiated platform and substantial market opportunity position us well to deliver long-term, sustainable growth. Our growth and margin guidance for the full year remains unchanged. We enter the second half in a strong position; new and enlarged contract wins, such as PRECISE and Plasmidsaurus, coupled with the increased productivity of our sales teams in the second quarter reinforces our confidence in delivering between 20 - 30% underlying revenue growth on a constant currency basis in full year 2024."

H1 Financial highlights

· Revenue of £84.1million was broadly flat at constant currency (CC), down 2.2% on a reported basis, in-line with expectations.

· Underlying revenue, excluding an £8.9 million combined headwind from COVID sequencing and the Emirati Genome Program (EGP); increased by 12.4% CC.

o Underlying revenue growth delivered in all regions, led by the EMEAI and APAC, with underlying growth of 16.4% and 10.6% respectively.

o Underlying revenue grew fastest across the PromethION product range[1], up 39.0% in the period to £31.9 million (H1 23: £23.0 million). Underlying revenue from the MinION product range[2] declined by 10.8% to £27.8 million (H1 23: £31.1 million) which includes a currency headwind and a mix of commercial and product specific factors. Other revenues, representing kits, services revenues and other devices grew 6.4% on an underlying basis to £22.9 million (H1 23: £21.5 million).

· Gross margin increased by 120 basis points (bps) to 58.8% (H1 23: 57.6%) driven by underlying margin improvements (380bps), particularly across both PromethION Flow Cell and devices, offsetting product mix (140bps) and currency (120bps) headwinds.

· Adjusted EBITDA loss of £(61.6) million (H1 23: £(39.4 million); driven by increasing operational expenses, primarily the annualised impact of additional headcount as highlighted at FY23 results. Adjusted operating costs were broadly flat (+2.0%) against H2 2023, demonstrating good cost control and with EBITDA loss lower than H2 2023 (£65.6m).

· Increase in loss year-on-year to £(74.7) million (H1 23: £(70.1) million). This was predominately driven by increasing operational expenses associated with the increase in headcount partly offset by a lower Founder LTIP charge of £1.0m (H1 23: £14.9 million) and a £5.5 million credit relating to the reversal of historic employers' social security tax charges (H1 23: £1.3 million).

· Strong balance sheet position; cash, cash equivalents and other liquid investments of £397.1 million[3] as at 30f June 2024, compared to £472.1 million as of 31 December 2023. Post period end the Group raised net proceeds of £78.2 million, following the successful completion of a multiple times oversubscribed £80.0 million equity placing, which included a new £50.0 million strategic investment from Novo Holdings.

H1 Business highlights

· Continued commercial progress in the period, evidenced by improving utilisation across existing customers, leading to a growing revenue opportunity for the Group driven by the enlarged and now established commercial infrastructure.


· New contract wins and contract expansions with larger PromethION devices (P24 and P48), including Precision Health Research Singapore (PRECISE), which selected Oxford Nanopore technology to sequence 10,000 long read human genomes to gain deeper insights into Asian genetic diversity, and a multi-million, multi-year contract expansion with Plasmidsaurus, to deliver high-accuracy whole plasmid sequencing with fast turnaround times.


· New strategic collaborations added to develop and access new growth markets in biopharma, clinical and industrial applications, including a collaboration with Lonza on a novel test to accelerate analysis of mRNA products.


· Progress was made to advance existing collaborations in H1, including with bioMérieux. A test for determining antibiotic resistance in tuberculosis is expected to be released as a research-use only product in Q4, prior to seeking IVD approvals by the end of 2025.


· Early Access[4] launch of PromethION 2 Integrated (P2i) in Q2, and continued rollout of the PromethION 2 Solo (P2S), following its successful launch in 2023. Evidence of continued market traction and disruption with more than 1,350 P2 devices now in the field. The P2 devices represent a new market area of affordable, accessible and high output sequencing.


· Strong progress against our 2024 innovation goals, with the launch of new products from our regulated pipeline, including GridION Q-Line and the Early Access of ElysION, our sample-to-answer automated sequencing solution, to drive adoption in new clinical and applied industrial markets.


· Approximately 1,400 peer-reviewed research papers published by users of Oxford Nanopore technology in H1 2024, bringing the total to approximately 12,500 to date, showcasing breakthrough research across cancer, human genetics and infectious disease and demonstrating continued opportunity for growth in the genomics research market.


· Expansion of the leadership team, to support the business in its next phase of growth: Nick Keher appointed as CFO and Director of Oxford Nanopore in January, adding significant financial leadership experience and a deep understanding of global capital markets. Nick succeeds Tim Cowper, who moves into a new role as Chief Operating Officer and will lead Oxford Nanopore's continuous improvement programmes and expanding international footprint and operations.

[bamboo2] 30/8/2024 16:12

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company behind a new generation of molecular sensing technology based on nanopores, will announce its interim results for the six months ended 30 June 2024, on Tuesday 3 September 2024.

Management will host a virtual presentation on the same day, at 10:00am BST/ 5:00am EDT, followed by a Q&A session, accessible via conference call or webcast. To access the webcast please register via this link.


The webcast will also be available on Oxford Nanopore's website at


The same link will provide access to a replay of the webcast shortly after the event concludes.

[seball] 29/8/2024 11:54

NOVO on why they bought into Oxford Nanopore.. Strong Buy

[brucie5] 21/8/2024 15:46

For the record, this is where the share price should SHOOT UP, since I am temporarily out.
;)

[bamboo2] 20/8/2024 19:40

Less technical resources are available online, for those who want to gen up and get some background knowledge.

One such provider is NHGRI or National Human Genome Research Institute in the US.

Extract.

"Many people have an illness, or several illnesses, that are affected by changes in either one or many of their genes, frequently coupled with environmental factors.

Researchers are studying these changes to understand the role that genetics plays in diseases across different populations.

A “polygenic risk score” is one way by which people can learn about their risk of developing a disease, based on the total number of changes related to the disease."

Learn more about genomic variants and their influence on human health...

[bamboo2] 20/8/2024 18:14

TR-1 Oracle, aka Larry Ellison etc

Reducing from 3.75% [35,294,117] to 3.004100% [28,265,044]

[brucie5] 20/8/2024 08:07

Thanks Bamboo. I cannot pretend to understand the half of what this tech actually does and is capable of doing but I do have the very strong hunch that it is rapidly making itself indispensible. It is the atm the only share I personally hold without a dividend, though this may change shortly as CWR looks ready once again to relaunch.

[bamboo2] 19/8/2024 20:55

Forensics have been noted as a potential use for Nanopore for the last three years, and featured during London Calling at some point. I am not aware of any other development work at the moment.

New Monkey Pox testing protocols using Nanopore are arriving thick and fast as labs are updating and revamping other virus sequencing methods. Both the US [Yale] and EU members have been active over recent weeks. The Netherlands [University hospital Amsterdam] has been designing a very rapid approach that will allow affordable outbreak control.

[brucie5] 19/8/2024 17:41

Hmm. Interesting if obvious dimension to genetic testing - forensic data bases. Does ONT have other such contracts?

[bamboo2] 19/8/2024 12:25

Dubai Police has formalized a significant partnership with Oxford Nanopore Technologies, based in Oxford, UK, by signing a Memorandum of Understanding (MoU) aimed at enhancing cooperation in education, training, and research and development.

The MoU was signed by His Excellency Major General Ahmad Thani Bin Ghalita, Director of the General Department of Forensic Sciences and Criminology at Dubai Police, and Phil Watkins, Vice President of Finance at Oxford Nanopore Technologies plc. This agreement marks a milestone in fostering collaborative efforts between the two entities.

Major General Bin Ghalita emphasized that this agreement underscores Dubai Police's dedication to advancing research and development as well as promoting knowledge exchange across various disciplines, particularly in forensic science and criminology. He highlighted that such partnerships are pivotal for learning from diverse experiences and practices, which can significantly enhance the capabilities of the laboratories and specialized units within the General Department of Forensic Sciences and Criminology.

Full article...